Lapatinib is a reversible, first-generation inhibitor of EGFR type 1 (HER1) and type 2 (HER2), administered orally and approved for the treatment of breast cancer overexpressing HER2 in combination with capecitabine [28]. Here, ERBB2 is linked to breast carcinoma.